4-[2-(2-氟-4-硝基苯氧基)乙基]吗啉 | 647858-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[2-(2-氟-4-硝基苯氧基)乙基]吗啉
• 英文名称: 4-(2-(2-fluoro-4-nitrophenoxy)ethyl)morpholine
• 英文别名: 4-[2-(2-Fluoro-4-nitrophenoxy)ethyl]morpholine；4-[2-(2-fluoro-4-nitrophenoxy)ethyl]morpholine
• CAS: 647858-38-6
• 化学式: C₁₂H₁₅FN₂O₄
• 分子量: 270.261
• InChiKey: PIDSMXVVFIBSIG-UHFFFAOYSA-N

物化性质

• 沸点：
  413.9±45.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[2-(2-氟-4-硝基苯氧基)乙基]吗啉 在 palladium on activated charcoal 正丁基锂 、 氢气 、 sodium carbonate 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 30.0h， 生成 (R)-3-[3-Fluoro-4-(2-morpholin-4-yl-ethoxy)-phenyl]-5-hydroxymethyl-oxazolidin-2-one
  参考文献：
  名称：

  乙烯-氧间隔基团对利奈唑胺活性的影响：具有硫羰基的强效抗菌剂的合成。

  摘要：

  报道了乙烯-氧间隔基元素在利奈唑胺的杂环和芳环之间的影响。这种间隔基的引入产生了具有较差的抗菌活性的化合物。然而，存在于利奈唑胺类似物中的乙酰胺基团向硫代氨基甲酸酯或硫代乙酰胺官能团的转化恢复了活性。介绍了具有乙烯-氧间隔基团的利奈唑胺类似物的合成以及具有不同杂环的SAR研究以及一些具有强抗菌特性的硫代羰基化合物的制备。

  DOI：

  10.1016/j.bmcl.2003.08.068
• 作为产物：
  描述：

  2-(2-氟-4-硝基苯氧基)乙醇 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4-[2-(2-氟-4-硝基苯氧基)乙基]吗啉
  参考文献：
  名称：

  乙烯-氧间隔基团对利奈唑胺活性的影响：具有硫羰基的强效抗菌剂的合成。

  摘要：

  报道了乙烯-氧间隔基元素在利奈唑胺的杂环和芳环之间的影响。这种间隔基的引入产生了具有较差的抗菌活性的化合物。然而，存在于利奈唑胺类似物中的乙酰胺基团向硫代氨基甲酸酯或硫代乙酰胺官能团的转化恢复了活性。介绍了具有乙烯-氧间隔基团的利奈唑胺类似物的合成以及具有不同杂环的SAR研究以及一些具有强抗菌特性的硫代羰基化合物的制备。

  DOI：

  10.1016/j.bmcl.2003.08.068

文献信息

• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014012360A1

  公开（公告）日：2014-01-23

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• [EN] 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2,4-DIAMINOPYRIMIDINE EN TANT QU'INHIBITEURS DE PROTÉINE KINASES
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2012059932A1

  公开（公告）日：2012-05-10

  The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

  本发明涉及一种新型的式（I）的嘧啶衍生物，其作为激酶抑制剂具有用途。更具体地，本发明涉及新型嘧啶化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗增殖性疾病中的用途。
• Nitrogenous heterocyclic derivatives and their application in drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US09434695B2

  公开（公告）日：2016-09-06

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型的含氮杂环化合物，其制备方法以及作为药物的用途，尤其是用于治疗和预防组织纤维化。本发明还提供了包含该含氮杂环化合物的药学上可接受的组合物，以及在人类或动物组织纤维化治疗中使用该组合物的用途，尤其是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、手术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化症、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化等方面的用途。
• Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies
  作者：Wen Lu、Pengfei Li、Yuanyuan Shan、Ping Su、Jinfeng Wang、Yaling Shi、Jie Zhang

  DOI：10.1016/j.bmc.2015.01.006

  日期：2015.3

  VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 mu M and 5.98 mu M, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.